Hace poco tiempo leímos (por encima) Outpatient Management of COVID-19: Rapid Evidence Review y nos quedamos con una frase en una las “Key recommendations”:
Remdesivir (Veklury) shortens time to recovery in hospitalized patients with COVID-19 but has not been proven to reduce mortality
Al leer en noviembre Remdesivir for the Treatment of Covid-19 — Final Report, nos atrajeron las conclusiones del resumen:
Our data show that remdesivir was superior to placebo in shortening the time to recovery in adults who were hospitalized with Covid-19 and had evidence of lower respiratory tract infection
y decidimos leer un poco más desde una perspectiva crítica.
No hay comentarios:
Publicar un comentario